dipyridamole has been researched along with Cardiotoxicity in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Doxorubicin caused cardiotoxicity as indicated by a significant increase in tumor necrosis factor-α, interleukin-6, malondialdehyde, and caspase-3 level (P<0." | 8.12 | Dipyridamole ameliorates doxorubicin-induced cardiotoxicity. ( Alyasiry, E; Hadi, N; Janabi, A, 2022) |
| " Doxorubicin caused cardiotoxicity as indicated by a significant increase in tumor necrosis factor-α, interleukin-6, malondialdehyde, and caspase-3 level (P<0." | 4.12 | Dipyridamole ameliorates doxorubicin-induced cardiotoxicity. ( Alyasiry, E; Hadi, N; Janabi, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alyasiry, E | 3 |
| Janabi, A | 3 |
| Hadi, N | 3 |
| MARINO, A | 1 |
2 other studies available for dipyridamole and Cardiotoxicity
| Article | Year |
|---|---|
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Dipyridamole; Doxorubicin; Interleukin | 2022 |
INFLUENCE OF PSYCHOLOGICAL STRESS ON THE SPECIFIC CARDIOTOXICITY OF DRUGS.
Topics: Angiotensins; Antihypertensive Agents; Carbamates; Cardiotoxicity; Dipyridamole; Electrocardiography | 1964 |